Skip to main content

What is CBD Oil?

Cannabidiol, or CBD oil, is a chemical present in the cannabis plant. It’s the non-psychoactive part of the plant, meaning it won’t get you high. (THC is the psychoactive compound.)

CBD comes in many different forms, from edible gummies, CBD oil, tinctures and topical creams. Most people take CBD orally via a dropper, but it can also be vaped or applied topically. It’s also available in pill form as an FDA-approved drug called Epidiolex to treat rare forms of epilepsy.

CBD is indeed legal in all 50 states of America. However, you must make sure that it is derived from hemp instead of marijuana, and it means that your CBD product must contain 0% THC to be legal in all 50 states.


What are the Benefits of CBD?

The benefits of CBD have been widely reported and include pain relief, reduced anxiety, improved sleep and overall better health. Below we have linked medical findings, studies and reviews of information available about CBD oil use. Some of the top scientific findings on the benefits of CBD highlight CBD use for these areas of health and wellness:

Pain reliefCBD oil has been shown to reduce chronic pain by interacting with specific receptors found in the brain. It also acts as an anti-inflammatory which helps to reduce pain.

Heart healthResearch has shown that taking regular doses of CBD can help the heart pump more efficiently, reduce inflammation and protect against artery damage.

NeuroprotectiveCBD has been shown to help prevent damage to neurons in your brain, which can help prevent disorders such as Alzheimer’s and Parkinson’s disease.


What are the Side Effects of CBD?

CBD (cannabidiol) is one of the most popular supplements today. It’s being used to treat a wide variety of health conditions, and more and more people are trying it as an alternative to prescription medications.

But even though it’s growing in popularity, there are still a lot of questions about CBD. How does it work? Is it safe? Are there any side effects? These are all valid concerns that you should understand before taking CBD.

So let’s look at some of the most common side effects of using CBD. CBD is generally thought to be safe and non-addictive. However, some people may experience mild side effects from taking CBD. These include:

  • diarrhea
  • changes in appetite
  • fatigue
  • drowsiness
  • dry mouth

These symptoms will likely only occur when taking high doses of CBD. With that being said, it’s essential to talk to your doctor before trying CBD if you’re taking any medications.


How to Properly Take Your CBD Oil for Maximum Effectiveness?

Taking CBD oil is one of the simplest things you can do, and it is a very straightforward process that does not require any special preparation, equipment or skills.

Depending on how fast you want to feel the effects, you can take CBD differently. If you’re going to feel the impact of the CBD oil immediately, then vaping or smoking is the best way to go about it. 

Vaping This method provides instant results since absorption occurs in the lungs. You can use CBD vape juice with a vaporizer pen or e-cigarette to inhale it as smoke or vapor.

Ingesting You can put a few drops of CBD oil under your tongue and hold it there for a minute before swallowing it. When ingested, this method delivers the compound into your bloodstream via digestion through your liver. 


Finding the right CBD Oil and Potency is Important.

If you are interested in using CBD oil for a specific purpose, you may want to follow a multi-step process:

1. Research the different types of CBD oil and how they can use

2. Decide what kind of CBD oil might be best for your purposes.

3. Choose a high-quality product with a trusted brand name and an effective formulation.

4. Start small and work up to larger doses until you find an amount that works.

5. Consider purchasing products from multiple brands to see what works best for you and to develop a tolerance to different outcomes if one is unavailable when you need it most.

6. Consult a medical doctor when considering CBD oil use, especially if you are pregnant, nursing, taking medication, or have a pre-existing or other medical condition.

Vibe by California offers over 500+ premium cannabis products in a dispensary near by in over 7 locations throughout California and Oregon. Each Vibe Cannabis Dispensary offers online shopping for easy pick-up in store or choose free delivery and have Vibe bring the cannabis products to you. Vibe cannabis dispensaries are open 7 days and open late to better serve you and your cannabis needs.

Information on this website is shared for educational purposes only.

The information on this website has not been evaluated by the Food & Drug Administration or any other medical body. We do not aim to diagnose, treat, cure or prevent any illness or disease. Consult a medical doctor before acting on any information gathered on this website, especially if you are pregnant, nursing, taking medication, or have a pre-existing or other medical condition.

For further reading about CBD please refer to the references below.

Papers of particular interest on CBD, published recently, have been outlined and links provided to medical studies and research available.


1.•• Bridgeman MB, Abazia DT. Medicinal Cannabis: History, Pharmacology, And Implications for the Acute Care Setting. P T. 2017;42(3):180–8 (excellent review on Cannabinoids focused on pharmacology).

PubMed  PubMed Central  Google Scholar

1.•• Vučković S, Srebro D, Vujović KS, Vučetić Č, Prostran M. Cannabinoids and Pain: New Insights From Old Molecules. Front Pharmacol. 2018;9:1259 (excellent review on Cannabinoids and Pain).

Article  Google Scholar

1. Russo EB. Cannabinoids in the management of difficult to treat pain. There Clin Risk Manag. 2008;4(1):245–59.

CAS  Article  Google Scholar

1.Costa B, Trovato AE, Comelli F, Giagnoni G, Colleoni M. The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain. Eur J Pharmacol. 2007;556(1–3):75–83.

CAS  Article  Google Scholar

1.Kumar RN, Chambers WA, Pertwee RG. Pharmacological actions and therapeutic uses of cannabis and cannabinoids. Anaesthesia. 2001;56(11):1059–68.

CAS  Article  Google Scholar

1.Pacher P, Bátkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 2006;58(3):389–462.

CAS  Article  Google Scholar

1.Zou S, Kumar U. Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System. Int J Mol Sci. 2018;19(3):833 Published 2018 Mar 13.

Article  Google Scholar

1.Anand P, Whiteside G, Fowler CJ, Hohmann AG. Targeting CB2 receptors and the endocannabinoid system for the treatment of pain. Brain Res Rev. 2009;60(1):255–66.

CAS  Article  Google Scholar

1.Laprairie RB, Bagher AM, Kelly ME, Denovan-Wright EM. Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol. 2015;172(20):4790–805.

CAS  Article  Google Scholar

1.Hammell DC, Zhang LP, Ma F, , Abshire SM, McIlwrath S, Stinchcomb AL, Westlund KNet al. Transdermal cannabidiol reduces inflammation and pain-related behaviours in a rat model of arthritis. Eur J Pain. 2016;20(6):936–948.

CAS  Article  Google Scholar

1.Philpott HT, OʼBrien M, McDougall JJ. Attenuation of early phase inflammation by cannabidiol prevents pain and nerve damage in rat osteoarthritis. Pain. 2017;158(12):2442–51.

CAS  Article  Google Scholar

1.Malfait AM, Gallily R, Sumariwalla PF, , Malik AS, Andreakos E, Mechoulam R, Feldmann Met al. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci U S A. 2000;97(17):9561–9566.

CAS  Article  Google Scholar

1.Babalonis S, Haney M, Malcolm RJ, , Lofwall MR, Votaw VR, Sparenborg S, Walsh SLet al. Oral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers. Drug Alcohol Depend. 2017;172:9–13.

CAS  Article  Google Scholar

1.Sekar K, Pack A. Epidiolex as adjunct therapy for treatment of refractory epilepsy: a comprehensive review with a focus on adverse effects. F1000Res. 2019;8:F1000 Faculty Rev-234.

Article  Google Scholar

1.Russo E, Guy GW. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses. 2006;66(2):234–46.

CAS  Article  Google Scholar

1.Vermersch P, Trojano M. Tetrahydrocannabinol:Cannabidiol Oromucosal Spray for Multiple Sclerosis-Related Resistant Spasticity in Daily Practice. Eur Neurol. 2016;76(5–6):216–26.

CAS  Article  PubMed  Google Scholar

1.Nielsen S, Germanos R, Weier M, Pollard J, Degenhardt L, Hall W, et al. The Use of Cannabis and Cannabinoids in Treating Symptoms of Multiple Sclerosis: a Systematic Review of Reviews. Curr Neurol Neurosci Rep. 2018;18(2):8.

Article  Google Scholar

1.Ferrè L, Nuara A, Pavan G, Radaelli M, Moiola L, Rodegher M, et al. Efficacy and safety of nabiximols (Sativex(®)) on multiple sclerosis spasticity in a real-life Italian monocentric study. Neurol Sci. 2016;37(2):235–42.

Article  Google Scholar

1.Johnson JR, Lossignol D, Burnell-Nugent M, Fallon MT. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics. J Pain Symptom Manage. 2013;46(2):207–18.

Article  Google Scholar

1.Portenoy RK, Ganae-Motan ED, Allende S, Yanagihara R, Shaiova L, Weinstein S, et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. J Pain. 2012;13(5):438–49.

CAS  Article  Google Scholar

1.•• Lichtman AH, Lux EA, McQuade R, Rossetti S, Sanchez R, Sun W, et al. Results of a Double-Blind, Randomized, Placebo-Controlled Study of Nabiximols Oromucosal Spray as an Adjunctive Therapy in Advanced Cancer Patients with Chronic Uncontrolled Pain. J Pain Symptom Manage. 2018;55(2):179–188.e1 (excellent study on Cannabinoids and Cancer Pain).

Article  Google Scholar

1.Nurmikko TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ, Haines D. Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain. 2007;133(1–3):210–20.

CAS  Article  Google Scholar

1.Blake DR, Robson P, Ho M, Jubb RW, McCabe CS. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (Oxford). 2006;45(1):50–2.

CAS  Article  Google Scholar

1.Cannabinoid Buccal Spray for Chronic Non-Cancer or Neuropathic Pain: A Review of Clinical Effectiveness, Safety, and Guidelines. 2016 Sep 21;. Review.

2.Moulin D, Boulanger A, Clark AJ, Clarke H, Dao T, Finley GA, et al. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Res. Manag. 19:328–35.

Article  Google Scholar

1.Darkovska-Serafimovska M, Serafimovska T, Arsova-Sarafinovska Z, Stefanoski S, Keskovski Z, Balkanov T. Pharmacotherapeutic considerations for use of cannabinoids to relieve pain in patients with malignant diseases. J Pain Res. 2018;11:837–42.

Article  Google Scholar

1.The FDA Warning Letters and Test Results for Cannabidiol-Related Products.

Research paper available in PDF form for download here: fphar-08-00269

1.Plastic and Neuroprotective Mechanisms Involved in the Therapeutic Effects of Cannabidiol in Psychiatric Disorders

Alline C. Campos1*, Manoela V. Fogaça1, Franciele F. Scarante1, Sâmia R. L. Joca2, Amanda J. Sales2, Felipe V. Gomes3, Andreza B. Sonego1, Naielly S. Rodrigues1, IsmaelGalve-Roperh4,5 andFranciscoS.Guimarães1

1 Department of Pharmacology, Centre for Interdisciplinary Research on Applied Neurosciences (NAPNA), School of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil, 2 Department of Physical and Chemical, School of Pharmaceutical Science of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil, 3 Department of Neuroscience, University of Pittsburgh, Pittsburgh, PA, United States, 4 Department of Biochemistry and Molecular Biology I, School of Biology, Complutense University, Madrid, Spain, 5 Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas, Instituto de Universitario de Investigación en Neuroquímica and Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, Spain.

Frontiers in Pharmacology,  published: 23 May 2017 doi: 10.3389/fphar.2017.00269